| 1 | Chromothripsis-Mediated Small Cell Lung Carcinoma | 26.4 | 2 | Citations (PDF) |
| 2 | <i>TERT</i>
Expression and Clinical Outcome in Pulmonary Carcinoids | 17.1 | 0 | Citations (PDF) |
| 3 | Reply to P. de Boissieu et al | 17.1 | 0 | Citations (PDF) |
| 4 | Alveolar Differentiation Drives Resistance to <i>KRAS</i> Inhibition in Lung Adenocarcinoma | 26.4 | 11 | Citations (PDF) |
| 5 | SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer | 17.1 | 29 | Citations (PDF) |
| 6 | Immune-Related Colitis Is Associated with Fecal Microbial Dysbiosis and Can Be Mitigated by Fecal Microbiota Transplantation | 3.7 | 3 | Citations (PDF) |
| 7 | Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in
<i>KEAP1</i>
mutant lung cancer | 11.3 | 15 | Citations (PDF) |
| 8 | Molecular phenotyping of small cell lung cancer using targeted cfDNA profiling of transcriptional regulatory regions | 11.3 | 8 | Citations (PDF) |
| 9 | RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer | 17.1 | 10 | Citations (PDF) |
| 10 | Prognostic Implications of Small Cell Lung Cancer Transcriptional Subtyping for CNS Metastases | 2.1 | 2 | Citations (PDF) |
| 11 | A Phase I/II Study of Valemetostat (DS-3201b), an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small-Cell Lung Cancer | 6.4 | 2 | Citations (PDF) |
| 12 | Antibiotics are associated with worse outcomes in lung cancer patients treated with chemotherapy and immunotherapy | 6.9 | 4 | Citations (PDF) |
| 13 | Intratumoral Escherichia Is Associated With Improved Survival to Single-Agent Immune Checkpoint Inhibition in Patients With Advanced Non–Small-Cell Lung Cancer | 17.1 | 0 | Citations (PDF) |
| 14 | CDC7 inhibition impairs neuroendocrine transformation in lung and prostate tumors through MYC degradation | 26.3 | 4 | Citations (PDF) |
| 15 | Early Circulating Tumor DNA Shedding Kinetics for Prediction of Platinum Sensitivity in Patients With Small Cell Lung Cancer | 2.1 | 0 | Citations (PDF) |
| 16 | Combination of MDM2 and Targeted Kinase Inhibitors Results in Prolonged Tumor Control in Lung Adenocarcinomas With Oncogenic Tyrosine Kinase Drivers and <i>MDM2</i> Amplification | 2.1 | 0 | Citations (PDF) |
| 17 | ATR inhibition activates cancer cell cGAS/STING-interferon signaling and promotes antitumor immunity in small-cell lung cancer | 11.3 | 2 | Citations (PDF) |
| 18 | CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors | 40.1 | 10 | Citations (PDF) |
| 19 | The ectonucleotidase CD39 identifies tumor-reactive CD8+ T cells predictive of immune checkpoint blockade efficacy in human lung cancer | 22.7 | 47 | Citations (PDF) |
| 20 | Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors 2023, 11, e005007 | | 18 | Citations (PDF) |
| 21 | IL-18–secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models | 9.1 | 52 | Citations (PDF) |
| 22 | Tarlatamab: New Star on the Horizon for Small-Cell Lung Cancer? | 17.1 | 7 | Citations (PDF) |
| 23 | Breathing room – focusing on the ‘other’ lung cancer | 13.9 | 0 | Citations (PDF) |
| 24 | <i>De Novo</i> and Histologically Transformed Small-Cell Lung Cancer Is Sensitive to Lurbinectedin Treatment Through the Modulation of EMT and NOTCH Signaling Pathways | 6.4 | 8 | Citations (PDF) |
| 25 | Conserved transcriptional connectivity of regulatory T cells in the tumor microenvironment informs new combination cancer therapy strategies | 13.1 | 21 | Citations (PDF) |
| 26 | Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer | 6.4 | 10 | Citations (PDF) |
| 27 | Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: a cohort study 2023, 11, e006994 | | 3 | Citations (PDF) |
| 28 | Phase I Study of Entinostat, Atezolizumab, Carboplatin, and Etoposide in Previously Untreated Extensive-Stage Small Cell Lung Cancer, ETCTN 10399 | 3.6 | 7 | Citations (PDF) |
| 29 | Exportin 1 inhibition prevents neuroendocrine transformation through SOX2 down-regulation in lung and prostate cancers | 13.1 | 18 | Citations (PDF) |
| 30 | <i>Smarca4</i> Inactivation Promotes Lineage-Specific Transformation and Early Metastatic Features in the Lung | 26.4 | 55 | Citations (PDF) |
| 31 | Phase 1 Clinical Trial of Trametinib and Ponatinib in Patients With NSCLC Harboring KRAS Mutations | 1.0 | 5 | Citations (PDF) |
| 32 | Inhibition of XPO1 Sensitizes Small Cell Lung Cancer to First- and Second-Line Chemotherapy | 0.6 | 29 | Citations (PDF) |
| 33 | Molecular Imaging of Neuroendocrine Prostate Cancer by Targeting Delta-Like Ligand 3 | 6.6 | 28 | Citations (PDF) |
| 34 | Radioimmunotherapy Targeting Delta-like Ligand 3 in Small Cell Lung Cancer Exhibits Antitumor Efficacy with Low Toxicity | 6.4 | 30 | Citations (PDF) |
| 35 | Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patientsCell, 2022, 185, 563-575.e11 | 35.1 | 310 | Citations (PDF) |
| 36 | Inferring gene expression from cell-free DNA fragmentation profiles | 18.1 | 102 | Citations (PDF) |
| 37 | Genomic and transcriptomic analysis of a library of small cell lung cancer patient-derived xenografts | 14.1 | 28 | Citations (PDF) |
| 38 | Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer | 0.9 | 17 | Citations (PDF) |
| 39 | Rationale and Design of the Phase 3 KEYLYNK-013 Study of Pembrolizumab With Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Limited-Stage Small-Cell Lung Cancer | 2.8 | 6 | Citations (PDF) |
| 40 | Ultrasmall Nanoparticle Delivery of Doxorubicin Improves Therapeutic Index for High-Grade Glioma | 6.4 | 11 | Citations (PDF) |
| 41 | WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC | 6.4 | 63 | Citations (PDF) |
| 42 | POU2F3 in SCLC: Clinicopathologic and Genomic Analysis With a Focus on Its Diagnostic Utility in Neuroendocrine-Low SCLC | 1.1 | 41 | Citations (PDF) |
| 43 | Abstract 6238: Profiling of the circulating cell-free DNA methylome for detection and subtyping of small cell lung cancers | 0.6 | 1 | Citations (PDF) |
| 44 | Selpercatinib-Induced Hypothyroidism Through Off-Target Inhibition of Type 2 Iodothyronine Deiodinase | 2.1 | 8 | Citations (PDF) |
| 45 | Targeting Lysine-Specific Demethylase 1 Rescues Major Histocompatibility Complex Class I Antigen Presentation and Overcomes Programmed Death-Ligand 1 Blockade Resistance in SCLC | 1.1 | 58 | Citations (PDF) |
| 46 | Delta-like ligand 3–targeted radioimmunotherapy for neuroendocrine prostate cancer | 7.7 | 31 | Citations (PDF) |
| 47 | Systemic and Oligo-Acquired Resistance to PD-(L)1 Blockade in Lung Cancer | 6.4 | 25 | Citations (PDF) |
| 48 | PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry | 26.4 | 20 | Citations (PDF) |
| 49 | Rb Tumor Suppressor in Small Cell Lung Cancer: Combined Genomic and IHC Analysis with a Description of a Distinct Rb-Proficient Subset | 6.4 | 44 | Citations (PDF) |
| 50 | Regulation of neuroendocrine plasticity by the RNA-binding protein ZFP36L1 | 14.1 | 18 | Citations (PDF) |
| 51 | cfDNA methylome profiling for detection and subtyping of small cell lung cancers | 13.9 | 64 | Citations (PDF) |
| 52 | Neuroendocrine neoplasms of the lung and gastrointestinal system: convergent biology and a path to better therapies | 25.3 | 19 | Citations (PDF) |
| 53 | Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer | 25.6 | 74 | Citations (PDF) |
| 54 | Advances in Small-Cell Lung Cancer (SCLC) Translational Research | 6.7 | 36 | Citations (PDF) |
| 55 | A Self-Assembling and Disassembling (SADA) Bispecific Antibody (BsAb) Platform for Curative Two-step Pretargeted Radioimmunotherapy | 6.4 | 28 | Citations (PDF) |
| 56 | Targeting Germline- and Tumor-Associated Nucleotide Excision Repair Defects in Cancer | 6.4 | 20 | Citations (PDF) |
| 57 | <i>MET</i> Exon 14–altered Lung Cancers and MET Inhibitor Resistance | 6.4 | 44 | Citations (PDF) |
| 58 | A Call to Action: Dismantling Racial Injustices in Preclinical Research and Clinical Care of Black Patients Living with Small Cell Lung Cancer | 26.4 | 10 | Citations (PDF) |
| 59 | TMEM41B Is a Pan-flavivirus Host FactorCell, 2021, 184, 133-148.e20 | 35.1 | 129 | Citations (PDF) |
| 60 | Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C–Mutant Non–Small Cell Lung Cancer | 6.4 | 75 | Citations (PDF) |
| 61 | <i>KRAS</i>
G12C Mutation Is Associated with Increased Risk of Recurrence in Surgically Resected Lung Adenocarcinoma | 6.4 | 24 | Citations (PDF) |
| 62 | Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with <i>EGFR</i> Exon 20 Insertions | 6.4 | 45 | Citations (PDF) |
| 63 | Synthesis and Comparative <i>In Vivo</i> Evaluation of Site-Specifically Labeled Radioimmunoconjugates for DLL3-Targeted ImmunoPET | 3.9 | 11 | Citations (PDF) |
| 64 | N-Linked Glycosylation on Anthrax Toxin Receptor 1 Is Essential for Seneca Valley Virus Infection | 3.3 | 6 | Citations (PDF) |
| 65 | ULK1 inhibition overcomes compromised antigen presentation and restores antitumor immunity in LKB1-mutant lung cancer | 13.9 | 88 | Citations (PDF) |
| 66 | Protein neddylation as a therapeutic target in pulmonary and extrapulmonary small cell carcinomas | 4.8 | 9 | Citations (PDF) |
| 67 | Multiomic Analysis of Lung Tumors Defines Pathways Activated in Neuroendocrine Transformation | 26.4 | 95 | Citations (PDF) |
| 68 | An optimized NGS sample preparation protocol for in vitro CRISPR screens | 1.1 | 2 | Citations (PDF) |
| 69 | Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS | 14.1 | 89 | Citations (PDF) |
| 70 | Abstract LB186: MAPK pathway activation represents a therapeutic vulnerability inASCL1-driven SCLC 2021, , | | 0 | Citations (PDF) |
| 71 | Tim-4+ cavity-resident macrophages impair anti-tumor CD8+ T cell immunity | 33.4 | 113 | Citations (PDF) |
| 72 | Quantitative <i>In Vivo</i> Analyses Reveal a Complex Pharmacogenomic Landscape in Lung Adenocarcinoma | 0.6 | 14 | Citations (PDF) |
| 73 | A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab | 26.4 | 320 | Citations (PDF) |
| 74 | <i>Rlf–Mycl</i> Gene Fusion Drives Tumorigenesis and Metastasis in a Mouse Model of Small Cell Lung Cancer | 26.4 | 26 | Citations (PDF) |
| 75 | Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions | 2.1 | 18 | Citations (PDF) |
| 76 | Targeting Aurora B kinase prevents and overcomes resistance to EGFR inhibitors in lung cancer by enhancing BIM- and PUMA-mediated apoptosis | 33.4 | 83 | Citations (PDF) |
| 77 | Small-cell lung cancer | 24.7 | 801 | Citations (PDF) |
| 78 | Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer | 33.4 | 204 | Citations (PDF) |
| 79 | Comprehensive molecular characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiation | 24.7 | 42 | Citations (PDF) |
| 80 | A CRISPR Activation Screen Identifies an Atypical Rho GTPase That Enhances Zika Viral Entry | 3.3 | 11 | Citations (PDF) |
| 81 | MAPK pathway activation selectively inhibits ASCL1-driven small cell lung cancer | 3.8 | 16 | Citations (PDF) |
| 82 | Immune biomarkers and response to checkpoint inhibition of BRAFV600 and BRAF non-V600 altered lung cancers | 5.7 | 14 | Citations (PDF) |
| 83 | SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic Sarcomas | 1.1 | 201 | Citations (PDF) |
| 84 | Utilization and factors precluding the initiation of consolidative durvalumab in unresectable stage III non-small cell lung cancer | 0.9 | 21 | Citations (PDF) |
| 85 | SCLC Subtypes Defined by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic Characterization | 1.1 | 293 | Citations (PDF) |
| 86 | Concurrent Mutations in STK11 and KEAP1 Promote Ferroptosis Protection and SCD1 Dependence in Lung Cancer | 6.4 | 144 | Citations (PDF) |
| 87 | CRISPR Gene Therapy: Applications, Limitations, and Implications for the Future | 2.7 | 331 | Citations (PDF) |
| 88 | Emergence of a High-Plasticity Cell State during Lung Cancer Evolution | 33.4 | 215 | Citations (PDF) |
| 89 | Molecular Engineering of Ultrasmall Silica Nanoparticle–Drug Conjugates as Lung Cancer Therapeutics | 6.4 | 19 | Citations (PDF) |
| 90 | Role of mTOR As an Essential Kinase in SCLC | 1.1 | 12 | Citations (PDF) |
| 91 | The Genomic Landscape of <i>SMARCA4</i> Alterations and Associations with Outcomes in Patients with Lung Cancer | 6.4 | 153 | Citations (PDF) |
| 92 | Extracellular Vesicle and Particle Biomarkers Define Multiple Human CancersCell, 2020, 182, 1044-1061.e18 | 35.1 | 789 | Citations (PDF) |
| 93 | Discovery of IPN60090, a Clinical Stage Selective Glutaminase-1 (GLS-1) Inhibitor with Excellent Pharmacokinetic and Physicochemical Properties | 6.9 | 60 | Citations (PDF) |
| 94 | Inherited Rare, Deleterious Variants in ATM Increase Lung Adenocarcinoma Risk | 1.1 | 26 | Citations (PDF) |
| 95 | Concurrent Targeting of Potential Cancer Stem Cells Regulating Pathways Sensitizes Lung Adenocarcinoma to Standard Chemotherapy | 1.7 | 8 | Citations (PDF) |
| 96 | CNS Metastases in Patients With <i>MET</i> Exon 14–Altered Lung Cancers and Outcomes With Crizotinib | 2.1 | 18 | Citations (PDF) |
| 97 | Protein-altering germline mutations implicate novel genes related to lung cancer development | 14.1 | 31 | Citations (PDF) |
| 98 | Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study | 17.1 | 487 | Citations (PDF) |
| 99 | Lineage plasticity in cancer: a shared pathway of therapeutic resistance | 25.3 | 309 | Citations (PDF) |
| 100 | Ultrasmall Core-Shell Silica Nanoparticles for Precision Drug Delivery in a High-Grade Malignant Brain Tumor Model | 6.4 | 68 | Citations (PDF) |
| 101 | Direct genome editing of patient-derived xenografts using CRISPR-Cas9 enables rapid in vivo functional genomics | 13.9 | 25 | Citations (PDF) |
| 102 | Epigenetic therapy inhibits metastases by disrupting premetastatic niches | 40.1 | 244 | Citations (PDF) |
| 103 | New Approaches to SCLC Therapy: From the Laboratory to the Clinic | 1.1 | 123 | Citations (PDF) |
| 104 | Regenerative lineages and immune-mediated pruning in lung cancer metastasis | 25.6 | 266 | Citations (PDF) |
| 105 | Eosinophilic Fasciitis Following Checkpoint Inhibitor Therapy: Four Cases and a Review of Literature | 3.6 | 44 | Citations (PDF) |
| 106 | A Phase II Trial of Albumin-Bound Paclitaxel and Gemcitabine in Patients with Newly Diagnosed Stage IV Squamous Cell Lung Cancers | 6.4 | 10 | Citations (PDF) |
| 107 | Clinical outcomes, local–regional control and the role for metastasis-directed therapies in stage III non-small cell lung cancers treated with chemoradiation and durvalumab | 0.9 | 44 | Citations (PDF) |
| 108 | Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC | 6.4 | 86 | Citations (PDF) |
| 109 | HER2-Mediated Internalization of Cytotoxic Agents in<i>ERBB2</i>Amplified or Mutant Lung Cancers | 26.4 | 180 | Citations (PDF) |
| 110 | SC-002 in patients with relapsed or refractory small cell lung cancer and large cell neuroendocrine carcinoma: Phase 1 study | 2.1 | 18 | Citations (PDF) |
| 111 | Targeted Therapies and Biomarkers in Small Cell Lung Cancer | 2.7 | 71 | Citations (PDF) |
| 112 | Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with <i>EGFR</i>-Mutant Lung Cancers | 6.4 | 263 | Citations (PDF) |
| 113 | Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes | 1.1 | 250 | Citations (PDF) |
| 114 | Lessons learned from routine, targeted assessment of liquid biopsies for <i>EGFR</i> T790M resistance mutation in patients with <i>EGFR</i> mutant lung cancers | 1.9 | 11 | Citations (PDF) |
| 115 | Circulating Tumor DNA Profiling in Small-Cell Lung Cancer Identifies Potentially Targetable Alterations | 6.4 | 41 | Citations (PDF) |
| 116 | Analyzing the Thin Tail: Searching for Biomarkers of Exceptional Survival in SCLC | 1.1 | 0 | Citations (PDF) |
| 117 | The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance | 6.4 | 235 | Citations (PDF) |
| 118 | Spread Through Air Spaces (STAS) Is Prognostic in Atypical Carcinoid, Large Cell Neuroendocrine Carcinoma, and Small Cell Carcinoma of the Lung | 1.1 | 66 | Citations (PDF) |
| 119 | Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study | 6.4 | 221 | Citations (PDF) |
| 120 | Tumour exosomal CEMIP protein promotes cancer cell colonization in brain metastasis | 10.5 | 289 | Citations (PDF) |
| 121 | Frequency and outcomes of brain metastases in patients with <i>HER2</i>‐mutant lung cancers | 4.4 | 61 | Citations (PDF) |
| 122 | Positron-Emission Tomographic Imaging of a Fluorine 18–Radiolabeled Poly(ADP-Ribose) Polymerase 1 Inhibitor Monitors the Therapeutic Efficacy of Talazoparib in SCLC Patient–Derived Xenografts | 1.1 | 16 | Citations (PDF) |
| 123 | Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study | 3.3 | 67 | Citations (PDF) |
| 124 | Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition | 5.5 | 141 | Citations (PDF) |
| 125 | ONECUT2 is a driver of neuroendocrine prostate cancer | 14.1 | 164 | Citations (PDF) |
| 126 | Immunophenotype and Response to Immunotherapy of <i>RET</i>-Rearranged Lung Cancers | 2.1 | 81 | Citations (PDF) |
| 127 | Acquired
<i>MET</i>
Exon 14 Alteration Drives Secondary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in
<i>EGFR</i>
-Mutated Lung Cancer | 2.1 | 39 | Citations (PDF) |
| 128 | Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers | 1.1 | 77 | Citations (PDF) |
| 129 | High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden | 6.4 | 318 | Citations (PDF) |
| 130 | Stage IV lung carcinoids: spectrum and evolution of proliferation rate, focusing on variants with elevated proliferation indices | 5.0 | 60 | Citations (PDF) |
| 131 | Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data | 24.2 | 760 | Citations (PDF) |
| 132 | Epigenetic targeting of DNA repair in lung cancer | 7.7 | 5 | Citations (PDF) |
| 133 | High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants | 25.6 | 497 | Citations (PDF) |
| 134 | Harnessing Clinical Sequencing Data for Survival Stratification of Patients With Metastatic Lung Adenocarcinomas | 2.1 | 27 | Citations (PDF) |
| 135 | Tumor mutational load predicts survival after immunotherapy across multiple cancer types | 16.3 | 2,692 | Citations (PDF) |
| 136 | Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14–mutant Non–small Cell Lung Cancer | 6.4 | 97 | Citations (PDF) |
| 137 | A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers | 5.1 | 102 | Citations (PDF) |
| 138 | Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors | 2.6 | 62 | Citations (PDF) |
| 139 | Peptide-based PET quantifies target engagement of PD-L1 therapeutics | 9.1 | 103 | Citations (PDF) |
| 140 | Response to ERBB3-Directed Targeted Therapy in <i>NRG1</i>-Rearranged Cancers | 26.4 | 158 | Citations (PDF) |
| 141 | Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer | 33.4 | 801 | Citations (PDF) |
| 142 | Target engagement imaging of PARP inhibitors in small-cell lung cancer | 14.1 | 72 | Citations (PDF) |
| 143 | Effects of Co-occurring Genomic Alterations on Outcomes in Patients with<i>KRAS</i>-Mutant Non–Small Cell Lung Cancer | 6.4 | 339 | Citations (PDF) |
| 144 | Small-Cell Carcinomas of the Bladder and Lung Are Characterized by a Convergent but Distinct Pathogenesis | 6.4 | 93 | Citations (PDF) |
| 145 | Acquired <i>ALK</i> and <i>RET</i> Gene Fusions as Mechanisms of Resistance to Osimertinib in <i>EGFR</i>-Mutant Lung Cancers | 2.1 | 71 | Citations (PDF) |
| 146 | Ado-Trastuzumab Emtansine for Patients With <i>HER2</i>-Mutant Lung Cancers: Results From a Phase II Basket Trial | 17.1 | 416 | Citations (PDF) |
| 147 | Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1 and Anti–Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing | 17.1 | 1,087 | Citations (PDF) |
| 148 | Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer | 17.1 | 301 | Citations (PDF) |
| 149 | <i>STK11/LKB1</i> Mutations and PD-1 Inhibitor Resistance in <i>KRAS</i>-Mutant Lung Adenocarcinoma | 26.4 | 1,145 | Citations (PDF) |
| 150 | Talazoparib Is a Potent Radiosensitizer in Small Cell Lung Cancer Cell Lines and Xenografts | 6.4 | 65 | Citations (PDF) |
| 151 | Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC | 3.7 | 269 | Citations (PDF) |
| 152 | Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer | 6.6 | 142 | Citations (PDF) |
| 153 | Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis | 33.4 | 385 | Citations (PDF) |
| 154 | Combined Inhibition of NEDD8-Activating Enzyme and mTOR Suppresses <i>NF2</i> Loss–Driven Tumorigenesis | 1.7 | 34 | Citations (PDF) |
| 155 | Noninvasive Interrogation of DLL3 Expression in Metastatic Small Cell Lung Cancer | 0.6 | 84 | Citations (PDF) |
| 156 | Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study | 21.9 | 428 | Citations (PDF) |
| 157 | Unravelling the biology of SCLC: implications for therapy | 25.3 | 332 | Citations (PDF) |
| 158 | Scientific Advances in Thoracic Oncology 2016 | 1.1 | 41 | Citations (PDF) |
| 159 | MA11.07 Improved Small Cell Lung Cancer (SCLC) Response Rates with Veliparib and Temozolomide: Results from a Phase II Trial | 1.1 | 12 | Citations (PDF) |
| 160 | Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies | 26.4 | 499 | Citations (PDF) |
| 161 | Histone Code Aberrancies in Small Cell Lung Cancer | 1.1 | 2 | Citations (PDF) |
| 162 | Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis | 25.6 | 480 | Citations (PDF) |
| 163 | Factors influencing the utilization of prophylactic cranial irradiation in patients with limited-stage small cell lung cancer | 1.4 | 37 | Citations (PDF) |
| 164 | A First-in-Class TWIST1 Inhibitor with Activity in Oncogene-Driven Lung Cancer | 2.9 | 67 | Citations (PDF) |
| 165 | Atezolizumab for the treatment of non-small cell lung cancer | 2.9 | 36 | Citations (PDF) |
| 166 | Patterns of failure in limited-stage small cell lung cancer: Implications of TNM stage for prophylactic cranial irradiation | 0.9 | 37 | Citations (PDF) |
| 167 | A comparison of FLT to FDG PET/CT in the early assessment of chemotherapy response in stages IB–IIIA resectable NSCLC | 2.7 | 16 | Citations (PDF) |
| 168 | Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non–Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations | 2.8 | 29 | Citations (PDF) |
| 169 | PARP Inhibitor Activity Correlates with <i>SLFN11</i> Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer | 6.4 | 265 | Citations (PDF) |
| 170 | Lung Adenocarcinoma: Predictive Value of<i>KRAS</i>Mutation Status in Assessing Local Recurrence in Patients Undergoing Image-guided Ablation | 9.6 | 25 | Citations (PDF) |
| 171 | Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy | 17.1 | 864 | Citations (PDF) |
| 172 | Capturing Genomic Evolution of Lung Cancers through Liquid Biopsy for Circulating Tumor DNA | 1.7 | 18 | Citations (PDF) |
| 173 | Anthrax toxin receptor 1 is the cellular receptor for Seneca Valley virus | 9.1 | 62 | Citations (PDF) |
| 174 | Liquid biopsy for ctDNA to revolutionize the care of patients with early stage lung cancers | 1.8 | 11 | Citations (PDF) |
| 175 | Small-cell lung cancer in the era of immunotherapy | 2.1 | 4 | Citations (PDF) |
| 176 | Pulmonary large cell neuroendocrine carcinoma with adenocarcinoma-like features: napsin A expression and genomic alterations | 5.0 | 49 | Citations (PDF) |
| 177 | Abstract CT115: Phase 1b <i>KEYNOTE 200 (STORM study):</i> A study of an intravenously delivered oncolytic virus, Coxsackievirus A21 in combination with pembrolizumab in advanced cancer patients | 0.6 | 12 | Citations (PDF) |
| 178 | Abstract 1727: Circulating Tumor Cells (CTCs) in patients with extensive stage small cell lung cancer and their association with clinical outcome 2017, , | | 0 | Citations (PDF) |
| 179 | CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer | 9.1 | 338 | Citations (PDF) |
| 180 | Quantitation of Murine Stroma and Selective Purification of the Human Tumor Component of Patient-Derived Xenografts for Genomic Analysis | 2.5 | 43 | Citations (PDF) |
| 181 | Missing the mark in <i>FGFR1</i>‐amplified squamous cell cancer of the lung | 4.4 | 7 | Citations (PDF) |
| 182 | Vismodegib or cixutumumab in combination with standard chemotherapy for patients with extensive‐stage small cell lung cancer: A trial of the ECOG‐ACRIN Cancer Research Group (E1508) | 4.4 | 58 | Citations (PDF) |
| 183 | P-selectin is a nanotherapeutic delivery target in the tumor microenvironment | 13.1 | 173 | Citations (PDF) |
| 184 | Cabozantinib in patients with advanced RET -rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial | 21.9 | 378 | Citations (PDF) |
| 185 | The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials | 2.1 | 11 | Citations (PDF) |
| 186 | A phase I trial of the Hedgehog inhibitor, sonidegib (LDE225), in combination with etoposide and cisplatin for the initial treatment of extensive stage small cell lung cancer | 2.1 | 58 | Citations (PDF) |
| 187 | A combinatorial strategy for treating KRAS-mutant lung cancer | 40.1 | 322 | Citations (PDF) |
| 188 | Medians and Milestones in Describing the Path to Cancer Cures | 13.6 | 38 | Citations (PDF) |
| 189 | Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and Outcomes | 2.8 | 114 | Citations (PDF) |
| 190 | Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline | 3.5 | 30 | Citations (PDF) |
| 191 | Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors | 6.4 | 49 | Citations (PDF) |
| 192 | Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes? | 1.1 | 144 | Citations (PDF) |
| 193 | Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma–like and Non–Small Cell Carcinoma–like Subsets | 6.4 | 343 | Citations (PDF) |
| 194 | Shining light on novel targets and therapies | 25.3 | 51 | Citations (PDF) |
| 195 | Abstract 3756: PARP inhibitor sensitivity in small cell lung cancer cell lines and patient-derived xenografts correlates with SLFN11 expression but not with structural homologous recombination deficiency 2016, , | | 0 | Citations (PDF) |
| 196 | Abstract 4356: Identification of the anthrax toxin receptor (ANTXR1) as the high affinity cellular receptor for Seneca Valley Virus (SVV) 2016, , | | 0 | Citations (PDF) |
| 197 | Abstract 4187: Loss of SLFN11 or gain of TWIST1 promote chemotherapy resistance in small cell lung cancer 2016, , | | 1 | Citations (PDF) |
| 198 | A Hyperactive Signalosome in Acute Myeloid Leukemia Drives Addiction to a Tumor-Specific Hsp90 Species | 6.4 | 54 | Citations (PDF) |
| 199 | Phase I trial of Seneca Valley Virus (NTX‐010) in children with relapsed/refractory solid tumors: A report of the Children's Oncology Group | 1.5 | 65 | Citations (PDF) |
| 200 | Evaluation of azacitidine and entinostat as sensitization agents to cytotoxic chemotherapy in preclinical models of non-small cell lung cancer | 1.7 | 26 | Citations (PDF) |
| 201 | Hedgehog Signaling Pathway Is Active in GBM with GLI1 mRNA Expression Showing a Single Continuous Distribution Rather than Discrete High/Low Clusters | 2.5 | 23 | Citations (PDF) |
| 202 | Seneca Valley Virus 3Cpro Substrate Optimization Yields Efficient Substrates for Use in Peptide-Prodrug Therapy | 2.5 | 7 | Citations (PDF) |
| 203 | RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer | 14.1 | 488 | Citations (PDF) |
| 204 | Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC | 1.3 | 177 | Citations (PDF) |
| 205 | Small cell lung cancer: Where do we go from here? | 4.4 | 465 | Citations (PDF) |
| 206 | The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies | 16.3 | 431 | Citations (PDF) |
| 207 | Effective treatment of diverse medulloblastoma models with mebendazole and its impact on tumor angiogenesis | 0.9 | 72 | Citations (PDF) |
| 208 | Repurposing the Antihelmintic Mebendazole as a Hedgehog Inhibitor | 1.7 | 72 | Citations (PDF) |
| 209 | A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer | 2.1 | 70 | Citations (PDF) |
| 210 | Genomic Analysis of Smoothened Inhibitor Resistance in Basal Cell Carcinoma | 33.4 | 305 | Citations (PDF) |
| 211 | Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring <i>MET</i> Mutations Causing Exon 14 Skipping | 26.4 | 502 | Citations (PDF) |
| 212 | Small Cell Lung Cancer: Will Recent Progress Lead to Improved Outcomes? | 6.4 | 178 | Citations (PDF) |
| 213 | Molecularly Targeted Therapies in Non–Small-Cell Lung Cancer Annual Update 2014 | 1.1 | 113 | Citations (PDF) |
| 214 | Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer | 25.5 | 7,770 | Citations (PDF) |
| 215 | Solid Predominant Histologic Subtype in Resected Stage I Lung Adenocarcinoma Is an Independent Predictor of Early, Extrathoracic, Multisite Recurrence and of Poor Postrecurrence Survival | 17.1 | 183 | Citations (PDF) |
| 216 | A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo | 13.1 | 438 | Citations (PDF) |
| 217 | Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline | 17.1 | 263 | Citations (PDF) |
| 218 | Preclinical oncology — reporting transparency needed | 25.3 | 2 | Citations (PDF) |
| 219 | Abstract 3752: Integrating proteomics and metabolomics characterizes active pathways and potential drug targets in small cell lung cancer | 0.6 | 2 | Citations (PDF) |
| 220 | Abstract LB-239: The Hippo effector YAP promotes resistance to RAF and MEK targeted therapies 2015, , | | 0 | Citations (PDF) |
| 221 | Abstract 610: Prospective genomic characterization of small cell lung cancer by targeted next generation sequencing 2015, , | | 0 | Citations (PDF) |
| 222 | Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer | 7.7 | 87 | Citations (PDF) |
| 223 | Combining the pan‐aurora kinase inhibitor <scp>AMG</scp> 900 with histone deacetylase inhibitors enhances antitumor activity in prostate cancer | 2.8 | 25 | Citations (PDF) |
| 224 | Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs | 13.7 | 1,376 | Citations (PDF) |
| 225 | Clinical Characteristics and Course of 63 Patients with BRAF Mutant Lung Cancers | 1.1 | 108 | Citations (PDF) |
| 226 | RET Mutations in Neuroendocrine Tumors: Including Small-Cell Lung Cancer | 1.1 | 12 | Citations (PDF) |
| 227 | A Randomized, Phase 2 Trial of Docetaxel with or without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Relapsed or Metastatic Non–Small-Cell Lung Cancer | 1.1 | 48 | Citations (PDF) |
| 228 | A Prospective Study of Tumor Suppressor Gene Methylation as a Prognostic Biomarker in Surgically Resected Stage I to IIIA Non–Small-Cell Lung Cancers | 1.1 | 31 | Citations (PDF) |
| 229 | Survival After Community Diagnosis of Early-stage Non-small Cell Lung Cancer | 2.1 | 51 | Citations (PDF) |
| 230 | Rapamycin Rescues ABT-737 Efficacy in Small Cell Lung Cancer | 0.6 | 48 | Citations (PDF) |
| 231 | SOX2 expression is an early event in a murine model of EGFR mutant lung cancer and promotes proliferation of a subset of EGFR mutant lung adenocarcinoma cell lines | 2.1 | 27 | Citations (PDF) |
| 232 | Systemic Therapy, Clinical Outcomes, and Overall Survival in Locally Advanced or Metastatic Pulmonary Carcinoid: A Brief Report | 1.1 | 33 | Citations (PDF) |
| 233 | Abstract A12: Screening for TWIST1 inhibitors as a novel therapy for oncogene-driven lung cancer. | 6.4 | 1 | Citations (PDF) |
| 234 | Abstract IA03: Genomic and epigenomic targets in small cell lung cancer. | 6.4 | 1 | Citations (PDF) |
| 235 | Abstract 4771: Identification of inhibitors of TWIST1 as a treatment for lung cancer 2014, , | | 0 | Citations (PDF) |
| 236 | Abstract 3405: E12 and E47 are essential for TWIST1 dependent suppression of oncogene-induced senescence in NSCLC 2014, , | | 0 | Citations (PDF) |
| 237 | Combination treatment with ABT-737 and chloroquine in preclinical models of small cell lung cancer | 29.8 | 38 | Citations (PDF) |
| 238 | Characteristics of Lung Cancers Harboring <i>NRAS</i> Mutations | 6.4 | 123 | Citations (PDF) |
| 239 | Hedgehog Pathway Inhibition Radiosensitizes Non-Small Cell Lung Cancers | 0.7 | 36 | Citations (PDF) |
| 240 | The future of epigenetic therapy in solid tumours—lessons from the past | 25.3 | 288 | Citations (PDF) |
| 241 | Itraconazole and Arsenic Trioxide Inhibit Hedgehog Pathway Activation and Tumor Growth Associated with Acquired Resistance to Smoothened Antagonists | 33.4 | 289 | Citations (PDF) |
| 242 | Epigenetic therapy in non-small-cell lung cancer: targeting DNA methyltransferases and histone deacetylases | 3.2 | 58 | Citations (PDF) |
| 243 | Phase 2 Study of Pemetrexed and Itraconazole as Second-Line Therapy for Metastatic Nonsquamous Non–Small-Cell Lung Cancer | 1.1 | 122 | Citations (PDF) |
| 244 | The Twist Box Domain Is Required for Twist1-induced Prostate Cancer Metastasis | 2.9 | 61 | Citations (PDF) |
| 245 | Selective Tropism of Seneca Valley Virus for Variant Subtype Small Cell Lung Cancer | 5.1 | 105 | Citations (PDF) |
| 246 | ERK Phosphorylation Is Predictive of Resistance to IGF-1R Inhibition in Small Cell Lung Cancer | 1.7 | 29 | Citations (PDF) |
| 247 | Phase I Study of the Hedgehog Pathway Inhibitor IPI-926 in Adult Patients with Solid Tumors | 6.4 | 143 | Citations (PDF) |
| 248 | Poly(β-amino ester) Nanoparticle Delivery of <i>TP53</i> Has Activity against Small Cell Lung Cancer <i>In Vitro</i> and <i>In Vivo</i> | 1.7 | 41 | Citations (PDF) |
| 249 | Inhibition of <i>TWIST1</i> Leads to Activation of Oncogene-Induced Senescence in Oncogene-Driven Non–Small Cell Lung Cancer | 2.9 | 50 | Citations (PDF) |
| 250 | Molecular Characterization of Acquired Resistance to the BRAF Inhibitor Dabrafenib in a Patient with BRAF-Mutant Non–Small-Cell Lung Cancer | 1.1 | 84 | Citations (PDF) |
| 251 | Small Cell Lung Cancer | 16.1 | 310 | Citations (PDF) |
| 252 | Abstract 4619: Epigenetic therapy and sensitization of lung cancer to immunotherapy. 2013, , | | 1 | Citations (PDF) |
| 253 | Aberrant Epigenetic Regulation: A Central Contributor to Lung Carcinogenesis and a New Therapeutic Target | 5.1 | 8 | Citations (PDF) |
| 254 | Alterations of immune response of non-small cell lung cancer with Azacytidine | 1.7 | 321 | Citations (PDF) |
| 255 | Abstract B45: The Twist box domain is required for Twist1-induced metastasis of prostate cancer cells 2013, , | | 0 | Citations (PDF) |
| 256 | Abstract 5644: Itraconazole and arsenic trioxide inhibit hedgehog pathway activation and tumor growth associated with acquired resistance to vismodegib. 2013, , | | 0 | Citations (PDF) |
| 257 | Abstract 5675: Optimization of a Seneca Valley Virus (SVV) 3C protease substrate for virus-directed enzyme prodrug therapy. 2013, , | | 0 | Citations (PDF) |
| 258 | Aberrant Epigenetic Regulation: A Central Contributor to Lung Carcinogenesis and a New Therapeutic Target | 5.1 | 3 | Citations (PDF) |
| 259 | Mobile Genetic Element Activation and Genotoxic Cancer Therapy | 1.1 | 13 | Citations (PDF) |
| 260 | Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma | 25.5 | 1,160 | Citations (PDF) |
| 261 | Twist1 Suppresses Senescence Programs and Thereby Accelerates and Maintains Mutant Kras-Induced Lung Tumorigenesis | 3.3 | 79 | Citations (PDF) |
| 262 | Vismodegib | 6.4 | 80 | Citations (PDF) |
| 263 | Therapeutic potential of Hedgehog signaling inhibitors in cancer: rationale and clinical data | 0.4 | 1 | Citations (PDF) |
| 264 | Characterization of a full-length infectious cDNA clone and a GFP reporter derivative of the oncolytic picornavirus SVV-001 | 3.5 | 24 | Citations (PDF) |
| 265 | Novel Therapeutic Approaches for Small Cell Lung Cancer: The Future has Arrived | 2.0 | 6 | Citations (PDF) |
| 266 | Crizotinib in the treatment of non-small-cell lung cancer | 2.3 | 79 | Citations (PDF) |
| 267 | Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer | 16.3 | 852 | Citations (PDF) |
| 268 | A Polymeric Nanoparticle Encapsulated Small-Molecule Inhibitor of Hedgehog Signaling (NanoHHI) Bypasses Secondary Mutational Resistance to Smoothened Antagonists | 1.7 | 71 | Citations (PDF) |
| 269 | Cigarette smoking and lung cancer—relative risk estimates for the major histological types from a pooled analysis of case–control studies | 4.5 | 390 | Citations (PDF) |
| 270 | Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer | 6.4 | 447 | Citations (PDF) |
| 271 | Abstract 1802: IGF-1R inhibition as a novel therapeutic strategy for small cell lung cancer 2012, , | | 0 | Citations (PDF) |
| 272 | Abstract 2954: TWIST1 is a critical mediator of KRAS mutant tumorigenesis in human non-small cell lung cancer 2012, , | | 0 | Citations (PDF) |
| 273 | Abstract 2049: Preclinical profile of AMG900 in combination with HDACIs in prostate cancer 2012, , | | 0 | Citations (PDF) |
| 274 | A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer | 2.1 | 82 | Citations (PDF) |
| 275 | Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors | 17.1 | 486 | Citations (PDF) |
| 276 | Itraconazole Side Chain Analogues: Structure–Activity Relationship Studies for Inhibition of Endothelial Cell Proliferation, Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) Glycosylation, and Hedgehog Signaling | 6.9 | 37 | Citations (PDF) |
| 277 | A Phase II Study of AT-101 (Gossypol) in Chemotherapy-Sensitive Recurrent Extensive-Stage Small Cell Lung Cancer | 1.1 | 136 | Citations (PDF) |
| 278 | DICER1 deficit induces Alu RNA toxicity in age-related macular degeneration | 40.1 | 521 | Citations (PDF) |
| 279 | Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Refractory, Locally Advanced or Metastatic Solid Tumors | 6.4 | 468 | Citations (PDF) |
| 280 | Phase I/II Study of Pemetrexed With or Without ABT-751 in Advanced or Metastatic Non–Small-Cell Lung Cancer | 17.1 | 42 | Citations (PDF) |
| 281 | Pharmacokinetics of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Locally Advanced or Metastatic Solid Tumors: the Role of Alpha-1-Acid Glycoprotein Binding | 6.4 | 101 | Citations (PDF) |
| 282 | Phase I Clinical Study of Seneca Valley Virus (SVV-001),a Replication-Competent Picornavirus, in Advanced Solid Tumors with Neuroendocrine Features | 6.4 | 124 | Citations (PDF) |
| 283 | Frequent detection of infectious xenotropic murine leukemia virus (XMLV) in human cultures established from mouse xenografts | 4.3 | 25 | Citations (PDF) |
| 284 | Notch Signaling Contributes to Lung Cancer Clonogenic Capacity <i>In Vitro</i> but May Be Circumvented in Tumorigenesis <i>In Vivo</i> | 2.9 | 36 | Citations (PDF) |
| 285 | Itraconazole Inhibits Angiogenesis and Tumor Growth in Non–Small Cell Lung Cancer | 0.6 | 134 | Citations (PDF) |
| 286 | Combination Epigenetic Therapy Has Efficacy in Patients with Refractory Advanced Non–Small Cell Lung Cancer | 26.4 | 571 | Citations (PDF) |
| 287 | Abstract 2557: Preclinical synergy of Plk1 inhibitors and HDACIs | 0.6 | 2 | Citations (PDF) |
| 288 | Abstract 5209: The roles of Notch signaling in the development of non-small cell lung cancer 2011, , | | 1 | Citations (PDF) |
| 289 | Abstract 3271: Inhibition of angiogenesis and tumor growth by itraconazole in primary xenograft models of human non-small cell lung cancer 2011, , | | 0 | Citations (PDF) |
| 290 | Abstract 4292: Frequent detection of xenotropic murine leukemia virus (XMLV) strains including XMRV in human cultures established from mouse xenografts 2011, , | | 0 | Citations (PDF) |
| 291 | A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies | 2.3 | 66 | Citations (PDF) |
| 292 | Geographic Proximity and Racial Disparities in Cancer Clinical Trial Participation | 16.1 | 29 | Citations (PDF) |
| 293 | The Impact of Insurance on Access to Cancer Clinical Trials at a Comprehensive Cancer Center | 6.4 | 35 | Citations (PDF) |
| 294 | Beyond the Scalpel: Targeting Hedgehog in Skin Cancer Prevention | 1.1 | 10 | Citations (PDF) |
| 295 | Skin Deep and Deeper: Multiple Pathways in Basal Cell Carcinogenesis | 1.1 | 6 | Citations (PDF) |
| 296 | Abstract 3738: Exploratory patient (pt) stratification markers associated with sensitivity to ABT-263 in small cell lung cancer (SCLC) 2010, , | | 0 | Citations (PDF) |
| 297 | Determinants of Apoptotic Sensitivity to HSP90 Inhibition In Acute Myeloid LeukemiaBlood, 2010, 116, 2159-2159 | 1.0 | 0 | Citations (PDF) |
| 298 | Cancer Stem Cells | 1.1 | 0 | Citations (PDF) |
| 299 | Dual Inhibition of the Epidermal Growth Factor Receptor Pathway with Cetuximab and Erlotinib: A Phase I Study in Patients with Advanced Solid Malignancies | 3.6 | 19 | Citations (PDF) |
| 300 | Lung Cancer in Never Smokers: A Call to Action: Fig. 1. | 6.4 | 33 | Citations (PDF) |
| 301 | Upregulation of <i>MMP-2</i> by HMGA1 Promotes Transformation in Undifferentiated, Large-Cell Lung Cancer | 2.9 | 66 | Citations (PDF) |
| 302 | Lung Cancer in Never Smokers: Molecular Profiles and Therapeutic Implications | 6.4 | 129 | Citations (PDF) |
| 303 | Lung Cancer in Never Smokers: Clinical Epidemiology and Environmental Risk Factors | 6.4 | 422 | Citations (PDF) |
| 304 | Randomized Phase II Study of Pulse Erlotinib Before or After Carboplatin and Paclitaxel in Current or Former Smokers With Advanced Non–Small-Cell Lung Cancer | 17.1 | 45 | Citations (PDF) |
| 305 | Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma | 25.5 | 947 | Citations (PDF) |
| 306 | Treatment of Medulloblastoma with Hedgehog Pathway Inhibitor GDC-0449 | 25.5 | 862 | Citations (PDF) |
| 307 | A Primary Xenograft Model of Small-Cell Lung Cancer Reveals Irreversible Changes in Gene Expression Imposed by Culture <i>In vitro</i> | 0.6 | 387 | Citations (PDF) |
| 308 | Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cellsBlood, 2009, 113, 2014-2021 | 1.0 | 172 | Citations (PDF) |
| 309 | Randomized Phase II Study of Carboplatin and Etoposide With or Without the<i>bcl-2</i>Antisense Oligonucleotide Oblimersen for Extensive-Stage Small-Cell Lung Cancer: CALGB 30103 | 17.1 | 142 | Citations (PDF) |
| 310 | Pharmacogenomic and Pharmacokinetic Determinants of Erlotinib Toxicity | 17.1 | 180 | Citations (PDF) |
| 311 | Therapeutic Efficacy of ABT-737, a Selective Inhibitor of BCL-2, in Small Cell Lung Cancer | 0.6 | 177 | Citations (PDF) |
| 312 | Phase I Study of Induction Chemotherapy and Concomitant Chemoradiotherapy with Irinotecan, Carboplatin, and Paclitaxel for Stage III Non-small Cell Lung Cancer | 1.1 | 6 | Citations (PDF) |
| 313 | Abstract LB-138: Efficacy data of GDC-0449, a systemic Hedgehog pathway antagonist, in a first-in-human, first-in-class Phase I study with locally advanced, multifocal or metastatic basal cell carcinoma patients | 0.6 | 7 | Citations (PDF) |
| 314 | SVF1 Regulates Cell Survival by Affecting Sphingolipid Metabolism in Saccharomyces cerevisiae | 4.2 | 18 | Citations (PDF) |
| 315 | Seneca Valley Virus, a Systemically Deliverable Oncolytic Picornavirus, and the Treatment of Neuroendocrine Cancers | 5.1 | 190 | Citations (PDF) |
| 316 | A Phase II Tolerability Study of Cisplatin Plus Docetaxel as Adjuvant Chemotherapy for Resected Non-small Cell Lung Cancer | 1.1 | 11 | Citations (PDF) |
| 317 | Fast, hungry and unstable: finding the Achilles’ heel of small-cell lung cancer | 10.0 | 25 | Citations (PDF) |
| 318 | P2-175: Phase 1/2 trial of ABT-751 in combination with pemetrexed vs pemetrexed alone in subjects with advanced or metastatic non-small-cell lung cancer (NSCLC) | 1.1 | 0 | Citations (PDF) |
| 319 | DNA cleavage and Trp53 differentially affect SINE transcription | 3.5 | 12 | Citations (PDF) |
| 320 | Phase II study of PKC-α antisense oligonucleotide aprinocarsen in combination with gemcitabine and carboplatin in patients with advanced non-small cell lung cancer | 2.1 | 30 | Citations (PDF) |
| 321 | A randomized, multicenter study to determine the safety and efficacy of the immunoconjugate SGN-15 plus docetaxel for the treatment of non-small cell lung carcinoma | 2.1 | 35 | Citations (PDF) |
| 322 | Phase II Trial of Temozolomide and Irinotecan as Second-Line Treatment for Advanced Non–small Cell Lung Cancer | 1.1 | 22 | Citations (PDF) |
| 323 | Phase I study of liposome-encapsulated c-raf antisense oligodeoxyribonucleotide infusion in combination with radiation therapy in patients with advanced malignancies. | 6.4 | 73 | Citations (PDF) |
| 324 | Surgical resection of limited disease small cell lung cancer in the new era of platinum chemotherapy: Its time has come | 2.9 | 142 | Citations (PDF) |
| 325 | Svf1 inhibits reactive oxygen species generation and promotes survival under conditions of oxidative stress inSaccharomyces cerevisiae | 2.4 | 26 | Citations (PDF) |
| 326 | Mammalian Target of Rapamycin Promotes Vincristine Resistance through Multiple Mechanisms Independent of Maintained Glycolytic Rate | 2.9 | 16 | Citations (PDF) |
| 327 | Phase I Study of G3139, a bcl-2 Antisense Oligonucleotide, Combined With Carboplatin and Etoposide in Patients With Small-Cell Lung Cancer | 17.1 | 150 | Citations (PDF) |
| 328 | Delivery of a Liposomal c-raf-1 Antisense Oligonucleotide by Weekly Bolus Dosing in Patients with Advanced Solid Tumors | 6.4 | 77 | Citations (PDF) |
| 329 | Genetic Variants in the <i>UDP-glucuronosyltransferase 1A1</i> Gene Predict the Risk of Severe Neutropenia of Irinotecan | 17.1 | 846 | Citations (PDF) |
| 330 | Akt Stimulates Aerobic Glycolysis in Cancer Cells | 0.6 | 1,206 | Citations (PDF) |
| 331 | Bcl-2 and Bcl-xL overexpression inhibits cytochrome c release, activation of multiple caspases, and virus release following coxsackievirus B3 infection | 2.3 | 100 | Citations (PDF) |
| 332 | Bcl-xL and Akt cooperate to promote leukemogenesis in vivo | 6.6 | 30 | Citations (PDF) |
| 333 | Human Alu element retrotransposition induced by genotoxic stress | 16.3 | 103 | Citations (PDF) |
| 334 | A phase II study of bryostatin-1 and paclitaxel in patients with advanced non-small cell lung cancer | 2.1 | 38 | Citations (PDF) |
| 335 | An Attenuated Adenovirus, ONYX-015, As Mouthwash Therapy for Premalignant Oral Dysplasia | 17.1 | 123 | Citations (PDF) |
| 336 | Bcl-x Complements Saccharomyces cerevisiae Genes That Facilitate the Switch from Glycolytic to Oxidative Metabolism | 2.3 | 58 | Citations (PDF) |
| 337 | Phase I Study of Dose-Dense Alternating Doublets in Advanced Non—Small-Cell Lung Cancer | 2.8 | 2 | Citations (PDF) |
| 338 | Carboplatin plus vinorelbine with concomitant radiation therapy in advanced non-small cell lung cancer: a phase I study | 2.1 | 15 | Citations (PDF) |
| 339 | Transcriptional activation of short interspersed elements by DNA-damaging agents | 3.5 | 109 | Citations (PDF) |
| 340 | Title is missing! | 2.6 | 18 | Citations (PDF) |
| 341 | Title is missing! | 2.6 | 20 | Citations (PDF) |
| 342 | A Phase I Study of STEALTH® Cisplatin (SPI-77) and Vinorelbine in Patients with Advanced Non–Small-Cell Lung Cancer | 2.8 | 15 | Citations (PDF) |
| 343 | Signal transduction pathways that regulate cell survival and cell death | 6.6 | 163 | Citations (PDF) |
| 344 | Bcl-xL and Bcl-2 expression in squamous cell carcinoma of the head and neck 1999, 85, 164-170 | | 103 | Citations (PDF) |
| 345 | APOPTOSIS AND DISEASE: Regulation and Clinical Relevance of Programmed Cell Death | 20.4 | 300 | Citations (PDF) |
| 346 | Apoptotic signaling in lymphocytes | 3.0 | 10 | Citations (PDF) |
